Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Carcinoma, Hepatocellular 3Solid Tumor 1Rectal Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Camurati-Engelmann Syndrome 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × LY-2157299 × Gastrointestinal × Clear all
NCT02734160 2019-08-05

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1 Completed
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01373164 2018-05-16

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
170 enrolled 25 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02154646 2016-02-10

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

Eli Lilly and Company

Phase 1 Completed
6 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡